Publications by authors named "K Galetta"

The Neurohospitalist Core Competencies comprise a set of competency-based learning objectives that encapsulate the knowledge, skills, and attitudes of neurohospitalitists who specialize in the care of hospitalized patients with neurologic conditions. These competencies serve to characterize the rapidly expanding field of neurohospitalist medicine. The 27 chapters are divided into 3 sections entitled: neurological conditions, clinical interventions and interpretation of ancillary studies, and neurohospitalist role in the healthcare system.

View Article and Find Full Text PDF

Background And Objectives: Immune checkpoint inhibitors (ICIs) are increasingly used against various cancers but are associated with immune-related adverse events (irAEs). Risk of irAEs may be higher in patients with certain preexisting autoimmune diseases, and these patients may also experience exacerbation of the underlying autoimmune disease following ICI initiation. People with multiple sclerosis (MS) have mostly been excluded from clinical trials of ICIs, so data on the safety of ICIs in MS are limited.

View Article and Find Full Text PDF

This study investigates the occurrence of inflammatory vaginitis in women with Multiple Sclerosis (wwMS) undergoing B-cell depleting therapy versus other disease-modifying therapies (DMTs). Retrospective analysis of medical records from Stanford University between 2015-2023 shows similar rates of vaginitis in both groups, suggesting no significant association with B-cell therapy. Despite this, inflammatory vaginitis remains prevalent in both treatment groups, warranting further investigation into its mechanisms and management.

View Article and Find Full Text PDF
Article Synopsis
  • Waldenström macroglobulinemia (WM) is a rare blood cancer marked by high levels of IgM and unusual immune cell presence in the bone marrow, and it can lead to rare complications like longitudinally extensive transverse myelitis (LETM).
  • A case study describes a 68-year-old man with untreated WM, experiencing symptoms of LETM, who showed significant improvement after treatment with ibrutinib and venetoclax, despite initial worsening during rituximab therapy.
  • The findings suggest that combining BTK (ibrutinib) and BCL2 (venetoclax) inhibitors could be effective for treating paraneoplastic LETM in WM, although more
View Article and Find Full Text PDF